Further supporting the role of USP30 in PD and its potential as a therapeutic target, several groups have designed, characterized, and investigated the effects and selectivity of a variety of USP30 inhibitors and found some that increased ubiquitination of Parkin targets and mitigated mitophagy [51,52,53,55,56]. This evidence concerns the gene PRKN and Parkinson disease.